Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company's pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrevimab, that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Invivyd Inc.

In a report released on March 19, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on Invivyd, with a price target of $10.00. The com...

Current Quarter	$-0.08	Next Quarter	$-0.09
Current Year	$-0.37	Next Year	$-0.26
QoQ Growth	-12.5%	YoY Growth	+29.7%
3Y EPS CAGR	+0.0%	Target Price	$10.00
Consensus	Buy	Upside	+649.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IVVD	$1.34	+3.49%	1.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IVVD	$1.34	+3.5%	1.33M
3
4
5
6

IVVD

IVVD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Invivyd Inc. Data in Excel

Get Invivyd Inc. Data in Excel